基本信息
浏览量:1
职业迁徙
个人简介
RESEARCH INTERESTS & PROJECTS
Regulation of host-microbiota symbiosis by intestinal mucin-type O-glycosylation
Our gastrointestinal (GI) tract represents perhaps the most “contaminated” environment our bodies could encounter, being home to ~ 10 trillion microbes across thousands of species, collectively termed the “commensal microbiota”. Incredibly, despite their close association with our tissues, our bodies normally not only tolerate these microbes (mostly bacteria), but require them for proper development and function of the GI tract, and even beyond. However, in some cases, this mutualistic interaction fails, leading potentially to disease.
My field of interest is focused on mechanisms of innate immunity in the gastrointestinal tract that promote protective responses against pathogens, while preventing unwanted inflammatory responses to our resident microbiota. Specifically, my research centers on the intestinal mucus system, a network of glycoproteins manufactured and secreted by goblet cells, and how defects in this system contribute to susceptibility to infections, inflammatory bowel disease (IBD), and colon cancer. To study this, I employ a repertoire of specialized skills to probe host-microbiota interactions in disease causation at the organismal, tissue, cellular and molecular level, including functional analysis of mucins and glycan biology, gut ecology; and state-of-the-art imaging and genetic modeling. Using these approaches (during my postdoctoral training at Oklahoma Medical Research Foundation) has led to novel insights into how the intestine utilizes two key glycosyltransferases, Core-1 β1,3 galatactosyltransferase (Core 1 synthase) and Core 3 β1,3N-acteylglucosaminyltransferase (Core 3 synthase), which decorate mucin proteins with sugars (aka glycans), to promote optimal mucus function that keeps the microbiota at a “healthy distance” from the gut, and prevent spontaneous IBD, as well as cancers of the colon and small intestine.
My independent studies build directly on this work, where I am addressing how the expression and activity of Core 1- and 3- synthases are controlled in humans and preclinical murine model systems; how mucin-type O-glycans impact the structure and function of microbial communities in the gut, and how O-glycans regulate formation and function of the intestinal mucus system. The goals of this work aim to increase our knowledge of the fundamental roles of mucins and their O-glycans in the gut, and devise novel methods of intervention to boost their protective capacities in IBD and cancer patients where defects in these systems are thought to contribute to pathogenesis.
Regulation of host-microbiota symbiosis by intestinal mucin-type O-glycosylation
Our gastrointestinal (GI) tract represents perhaps the most “contaminated” environment our bodies could encounter, being home to ~ 10 trillion microbes across thousands of species, collectively termed the “commensal microbiota”. Incredibly, despite their close association with our tissues, our bodies normally not only tolerate these microbes (mostly bacteria), but require them for proper development and function of the GI tract, and even beyond. However, in some cases, this mutualistic interaction fails, leading potentially to disease.
My field of interest is focused on mechanisms of innate immunity in the gastrointestinal tract that promote protective responses against pathogens, while preventing unwanted inflammatory responses to our resident microbiota. Specifically, my research centers on the intestinal mucus system, a network of glycoproteins manufactured and secreted by goblet cells, and how defects in this system contribute to susceptibility to infections, inflammatory bowel disease (IBD), and colon cancer. To study this, I employ a repertoire of specialized skills to probe host-microbiota interactions in disease causation at the organismal, tissue, cellular and molecular level, including functional analysis of mucins and glycan biology, gut ecology; and state-of-the-art imaging and genetic modeling. Using these approaches (during my postdoctoral training at Oklahoma Medical Research Foundation) has led to novel insights into how the intestine utilizes two key glycosyltransferases, Core-1 β1,3 galatactosyltransferase (Core 1 synthase) and Core 3 β1,3N-acteylglucosaminyltransferase (Core 3 synthase), which decorate mucin proteins with sugars (aka glycans), to promote optimal mucus function that keeps the microbiota at a “healthy distance” from the gut, and prevent spontaneous IBD, as well as cancers of the colon and small intestine.
My independent studies build directly on this work, where I am addressing how the expression and activity of Core 1- and 3- synthases are controlled in humans and preclinical murine model systems; how mucin-type O-glycans impact the structure and function of microbial communities in the gut, and how O-glycans regulate formation and function of the intestinal mucus system. The goals of this work aim to increase our knowledge of the fundamental roles of mucins and their O-glycans in the gut, and devise novel methods of intervention to boost their protective capacities in IBD and cancer patients where defects in these systems are thought to contribute to pathogenesis.
研究兴趣
论文共 51 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Seminars in immunology (2023): 101807-101807
Scientific Reportsno. 1 (2023): 13982-13982
Methods in molecular biology (Clifton, N.J.) (2023): 197-205
Noah Fancy, Darrek Kniffen, Mackenzie Melvin,Negin Kazemian, Javad Sadeghi, Clara A. Letef, Leah D'Aloisio, Amanda G. Copp,Kris Chadee,Sanjoy Ghosh,Deanna L. Gibson,Sepideh Pakpour,
引用0浏览0引用
0
0
Simin Jafaripour, Mackenzie Melvin, Irving Zhang,Colin Parrish,Brian Wasik,Negin Kazemian, Hannah Olsson,Sepideh Pakpour,Wesley F. Zandberg,Kirk Bergstrom
GLYCOBIOLOGYno. 11 (2023): 994-995
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn